Simlipid from Premier Biosoft International analyses lipid mass spectrometric data for characterising lipids and can annotate mass spectra with identified lipid structures and abbreviations
Premier Biosoft International has announced the worldwide release of version 2.92 of its MS data analysis tool, SimGlycan
Premier Biosoft International has released Beacon Designer version 7.7, featuring design support for high resolution melting analysis (HRMA) primers
Premier Biosoft International has released Primer Premier v6, which allows users to design highly specific standard PCR and SNP genotyping assays
Premier Biosoft International has released v7.50 of AlleleID, which enables xMAP users to design differentiation assays
Premier Biosoft International has released v2.7 of SimGlycan, an MS/MS data analysis tool that now supports the ability to draw and edit glycans and annotate MS spectra with cartoons for publication
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
